Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has earned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $13.25.

A number of research analysts recently issued reports on the company. HC Wainwright decreased their price objective on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, September 4th. Barclays decreased their price target on shares of Orchestra BioMed from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research report on Thursday, November 13th. BTIG Research restated a “neutral” rating on shares of Orchestra BioMed in a report on Wednesday, August 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th.

Orchestra BioMed Stock Up 2.4%

Orchestra BioMed stock opened at $4.23 on Friday. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $6.30. The company has a quick ratio of 4.72, a current ratio of 4.73 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average of $3.27 and a 200-day moving average of $3.02. The stock has a market capitalization of $238.85 million, a PE ratio of -2.32 and a beta of 0.65.

Orchestra BioMed (NASDAQ:OBIO) last announced its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $0.74 million. Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%. On average, equities research analysts anticipate that Orchestra BioMed will post -1.66 EPS for the current fiscal year.

Institutional Trading of Orchestra BioMed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Alyeska Investment Group L.P. bought a new position in Orchestra BioMed in the third quarter valued at approximately $3,386,000. Qube Research & Technologies Ltd acquired a new stake in shares of Orchestra BioMed in the 3rd quarter valued at approximately $64,000. Citadel Advisors LLC grew its stake in shares of Orchestra BioMed by 9.2% in the third quarter. Citadel Advisors LLC now owns 54,002 shares of the company’s stock valued at $134,000 after buying an additional 4,561 shares in the last quarter. Bank of America Corp DE increased its holdings in Orchestra BioMed by 44.2% during the third quarter. Bank of America Corp DE now owns 31,119 shares of the company’s stock worth $77,000 after buying an additional 9,542 shares during the last quarter. Finally, Pathstone Holdings LLC bought a new stake in Orchestra BioMed during the third quarter worth $2,495,000. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.